Sarcosine Improves Negative and Cognitive Symptoms in Schizophrenia, May Reverse Damage to Brain
A new study out of Poland’s Medical University of Lodz has found that 6 months of use of a nutritional supplement called sarcosine (N-Methylglycine) seems to reverse the damage to the brain’s glutamate system and improves the negative and cognitive symptoms (memory, concentration, social activity interest, motivation, etc. ) of people who have schizophrenia. This is just the latest of […]
Gray Matter Loss in Brain Due to Psychotic Episodes / Schizophrenia, Not From Medications
Its been noted for the past decade or so that there is some (approximately 5% to 7%) shrinkage in the brains of people who have schizophrenia, most notably in the gray matter, which is an important part structures in the brain’s amygdala, hippocampus and parahippocampus, which are all involved in memory storage and retrieval memory storage and […]
ADVERTISEMENT
Schizophrenia News Watch – August
Following is the most interesting news on schizophrenia that we’ve found in the past month or so: Voices – Documentary about Schizophrenia, Now Planning Screenings at a City Near You Check out the list of cities that are hosting screenings on the new documentary about schizophrenia. If there isn’t a screening in your city – […]
$650 Million Donated for Schizophrenia Research
In what has to be the biggest news in schizophrenia research in the past 3 decades, the philanthropist Ted Stanley announced that he is donating $650 Million for schizophrenia and bipolar disorder research (and related psychiatric research) to the Broad Institute. The focus of this unprecedented donation is on spurring on scientific research on the […]
Schizophrenia Special in Nature Journal
Phil Campbell, the editor-in-chief of the prestigious and high quality scientific journal “Nature,” (based in the UK) has long been interested in schizophrenia and mental health concerns. I’ve met him and discussed this interest last year when he was visiting the United States. He is one of the founding members of of an important new […]
New Study of Long-Acting Injectable Antipsychotics Finds Haloperidol an Effective, Less-Expensive Option
A new study done by Columbia University of long-acting injectable antipsychotics for people with schizophrenia found that the newer, second-generation, medication paliperidone palmitate (Brand name Invega Sustenna by Janssen Pharmaceuticals) was no more effective than the older, less expensive haloperidol decanoate. This was so, even though the doses of the older medication given in the […]
Antipsychotic Use Associated with 50% Reduced Rate of Violent Crime
While people with schizophrenia are much more likely to be victims of criminal behavior than perpetrators, there is a small percentage of people who have schizophrenia that are more violent; especially those who have a history of violence and who are abusing drugs or alcohol, and in those cases it is family members who are […]
Over 30 New Medications in Development for Schizophrenia
American biopharmaceutical research companies are currently developing almost 36 new medications for schizophrenia, and a total of 119 new medicines targeting mental health disorders, according to a new document by the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry marketing / advocacy organization for pharmaceutical and biotech companies in the USA. Some of the drugs listed […]
Schizophrenia News Watch – interesting newsbites from around the globe
With this new posting on “Schizophrenia News Watch” – we are initiating a periodic summary of interesting schizophrenia-related news from around the globe. In these postings we will provide short summaries and links to schizophrenia-related news, videos and presentations from around the world. Closer than ever to a cure for Schizophrenia: This is a good […]
New Report Demonstrates the Cost Effectiveness of Early Treatment
There has been a great deal of clinical research in the past decade that has shown that the sooner that people who have psychosis or schizophrenia are treated, the better their long term outcome or prognosis. So getting people into treatment as quickly as possible (when symptoms start to appear) is extremely important. Despite this […]
Minerva Neurosciences Raising $69 Million to Fund New Schizophrenia Medications
Minerva Neurosciences today filed to raise $69 million via an initial public offering (IPO). The proceeds from this fund raising will be used to further develop and test their new drug candidates that are targeted at schizophrenia, depression and other mental illnesses. We at schizophrenia.com think that its great to see new medications being developed […]
Cannabis-Derivative a Potential New Schizophrenia Treatment
There have been many research studies suggesting that marijuana may increase risk of schizophrenia (see here). But there is also a recent study at Harvard Medical School, led by Ashley C. Proal, that has suggested this may not be the case. This recent comparison between families with a history of schizophrenia and those without, found […]
Omeros Reports Positive Results from New Medication Phase 2 Clinical Trial for Schizophrenia
A new research report gives hope to families and people who suffer from schizophrenia that there may soon be a new medication that helps with the negative and cognitive symptoms that are so common with schizophrenia. Omeros Corporation recently announced additional positive results from a Phase 2a clinical trial of OMS824, the company’s phosphodiesterase 10 (PDE10) […]
